Cardiovascular Diseases Clinical Trial
To conduct a three-armed trial assessing the effect of soy phytoestrogens on menopausal complaints, plasma lipids and lipoproteins, vaginal bleeding and endometrial proliferation, and health related quality of life.
BACKGROUND:
The results of many studies indicate that estrogen replacement therapy (ERT) reduces the
risk of coronary heart disease (CHD) in postmenopausal women. However, less than 9 percent
of these women choose to take ERT because of unwanted side effects and concerns about
increased risk of cancer associated with ERT. Therefore, alternative therapies are needed.
The isoflavonoids found in soy protein (specifically genistein) have many properties that
may reduce the risk of coronary heart disease. These include favorable effects on plasma
lipids and coronary artery vasomotion. Furthermore, genistein is a tyrosine kinase (TK)
inhibitor with inhibitory effects on thrombin activity and TK receptor-linked mitogens that
may be associated with atherogenesis and neointimal formation after angioplasty.
DESIGN NARRATIVE:
Randomized, double-blind, placebo-controlled. The women were randomized into one of three
groups: placebo, conjugated equine estrogens, or soy supplementation. Primary endpoints were
the impact on menopausal complaints such as hot flushes, mood lability, anxiety, sleep
disturbances; effects on plasma lipids and lipoproteins, including lipoprotein (a); effects
on vaginal bleeding and endometrial proliferation; changes in health-related quality of
life. Secondary endpoints included: assessment of the impact of these interventions on the
progression of carotid artery intimal medial wall thickening as assessed by B-mode
ultrasonography; bone density and bone turnover; additional measures to monitor the
compliance and safety of the intervention such as mammography, anticipated or known side
effects of hormone replacement therapy, blood levels of genistein, and clinical outcomes
such as hospitalizations, physician visits, and symptoms. The study ended in December, 1998.
The study was a subproject within a program project on coronary atherosclerosis in females,
primarily monkeys. Dr. Thomas B. Clarkson was the P.I. The subproject dollars were estimated
based on the CRISP dollars assigned to the study which were approximately 12 percent of the
total program project dollars and were broken down as follows: FY 1996 - 219,254; FY 1997 -
$217,000; FY 1998 - $221,000.
The study completion date listed in this record was obtained from the "End Date" entered in
the Protocol Registration and Results System (PRS) record.
;
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|